+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
mRNA Cancer Vaccines & Therapeutics Market - Global Forecast 2026-2032- Product Image
mRNA Cancer Vaccines & Therapeutics Market - Global Forecast 2026-2032- Product Image
Sale

mRNA Cancer Vaccines & Therapeutics Market - Global Forecast 2026-2032

  • Report

  • 193 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6277896
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

mRNA Cancer Vaccines and Therapeutics: Executive Overview

mRNA cancer vaccines and therapeutics use messenger RNA to instruct cells to produce tumor-associated or tumor-specific antigens, immune modulators, or other therapeutic proteins. The field spans personalized neoantigen vaccines, shared-antigen approaches, cancer immunotherapies, and delivery systems designed to improve expression and tolerability. Clinical development is shaped by advances in sequencing, computational antigen selection, lipid-based delivery, manufacturing, and combination treatment strategies. Evidence remains differentiated by cancer type, clinical stage, endpoint, and platform, so interpretation should prioritize peer-reviewed results, registered trials, regulatory disclosures, and reproducible translational findings rather than headline announcements.

From Experimental Platforms to Integrated Oncology Workflows

The landscape is shifting from stand-alone platform validation toward integrated oncology workflows that connect biopsy collection, genomic analysis, antigen prioritization, formulation, manufacturing, quality control, and treatment delivery. Personalized products require coordinated logistics and dependable turnaround times, while off-the-shelf programs emphasize antigen selection, broad patient eligibility, and scalable production. Combination regimens with checkpoint inhibition, targeted therapy, radiotherapy, or standard chemotherapy are also being evaluated because immune priming and tumor microenvironment modulation may be complementary. Key constraints include tumor heterogeneity, immune escape, manufacturing complexity, clinical endpoint selection, and the need for durable evidence across diverse patient populations.

Artificial Intelligence Accelerates Design but Does Not Replace Validation

Artificial intelligence is being applied to neoantigen prediction, peptide-HLA binding assessment, antigen prioritization, biomarker discovery, patient stratification, trial recruitment, process optimization, and analysis of imaging or sequencing data. Its practical value depends on high-quality, representative datasets and transparent validation against clinical outcomes. Models can help reduce candidate-selection time and identify patterns across multimodal data, but they do not eliminate biological uncertainty, sampling bias, or the need for laboratory and prospective clinical confirmation. Leaders should therefore treat AI as a decision-support layer governed by traceability, human review, data protection, model monitoring, and clearly defined performance thresholds.

Regional Readiness Differs Across North America, Europe, and Asia-Pacific

North America combines strong translational research, advanced oncology infrastructure, venture participation, and regulatory experience, while access and reimbursement pathways remain important implementation considerations. Europe benefits from substantial academic collaboration and coordinated research networks, but national health-system variation can complicate adoption and evidence requirements. Asia-Pacific includes sophisticated biomedical hubs and major manufacturing capabilities alongside uneven access, regulatory maturity, and clinical-trial infrastructure. Latin America is building oncology research and biotechnology capacity, with patient access, funding continuity, and specialized logistics remaining central considerations. The Middle East is investing in healthcare modernization and precision medicine, while adoption depends on specialized workforce development and cross-border partnerships. Africa presents important unmet need and emerging research opportunities, but infrastructure, diagnostic capacity, affordability, and supply-chain resilience require sustained attention.

International Groups Shape Standards, Access, and Collaboration

ASEAN countries present a diverse combination of growing healthcare investment, varied regulatory systems, and differing oncology capacity, making regional harmonization and referral networks valuable. BRICS members combine large patient populations and significant scientific capabilities with varied access conditions, manufacturing strengths, and policy environments. The European Union supports multinational research and regulatory coordination, although implementation remains influenced by national assessment and reimbursement systems. G7 economies contribute advanced research, clinical infrastructure, and regulatory expertise, while their aging populations and healthcare-cost pressures heighten the need for robust value evidence. GCC states are strengthening precision-oncology capacity and centralized healthcare capabilities, with workforce and data-governance development remaining priorities. NATO members offer extensive research and healthcare networks, but collaboration must account for national regulation, security, procurement, and data-protection requirements.

Country-Level Priorities Range from Platform Leadership to Access Development

The United States combines deep clinical-research capacity, advanced biotechnology infrastructure, and complex evidence and reimbursement pathways. Canada contributes strong public research and oncology networks, with geography and health-system coordination affecting implementation. Germany, France, Italy, and Spain offer substantial European oncology expertise, while national assessment, procurement, and reimbursement processes shape adoption. The United Kingdom has notable genomic and health-technology capabilities, with evidence standards and health-service integration remaining central. China is expanding biopharmaceutical research, manufacturing, and clinical infrastructure; regulatory consistency and evidence comparability remain important. Japan and South Korea combine sophisticated healthcare and technology ecosystems, while demographic needs and regulatory coordination influence development. India offers extensive clinical talent, manufacturing potential, and a large oncology burden, with affordability and diagnostic access especially relevant. Australia has strong research institutions and trial capability but faces geographic access challenges. Brazil and Mexico are important Latin American oncology markets with developing research and production ecosystems, where affordability, regional access, and healthcare-system capacity are decisive. Russia retains scientific and clinical capabilities, while international collaboration, supply continuity, and regulatory conditions materially affect development pathways.

Build Evidence, Manufacturing, and Access into the Strategy from the Start

Industry leaders should establish an evidence architecture that links translational biomarkers to clinically meaningful endpoints and includes representative patient populations. They should design modular manufacturing and quality systems capable of supporting both personalized and standardized products, with validated release methods and resilient supply chains. Partnerships among cancer centers, sequencing providers, manufacturers, regulators, and health systems can reduce operational friction, particularly for time-sensitive personalized therapies. AI programs should use governed datasets, prospective validation, and clear accountability. Finally, organizations should plan for affordability, reimbursement, diagnostic readiness, cold-chain or specialized logistics, and clinician education early rather than treating access as a post-approval issue.

Evidence-Based Methodology for Assessing the Field

A rigorous assessment should triangulate peer-reviewed literature, public clinical-trial registries, regulatory documents, health-system publications, scientific-conference materials, patent records, and verified institutional disclosures. Findings should be classified by therapeutic concept, cancer indication, development stage, delivery technology, biomarker strategy, combination regimen, and evidence quality. Regional, group, and country comparisons should consider research capacity, regulatory environment, manufacturing infrastructure, diagnostic readiness, healthcare access, and policy conditions. Conflicting claims should be retained as uncertainty rather than resolved through unsupported assumptions. The analysis should exclude unverified promotional statements and avoid market estimates, market sizing, market shares, and forecasts.

Sustainable Progress Depends on Clinical Proof and System Readiness

mRNA cancer vaccines and therapeutics have moved into a more integrated phase of oncology innovation, supported by advances in immunology, genomics, delivery, and data science. However, durable patient benefit will depend on demonstrating consistent clinical value, overcoming tumor and immune-system complexity, and fitting products into real-world diagnostic, manufacturing, reimbursement, and care pathways. Regional and country conditions will shape how quickly capabilities translate into access. The strongest strategies will pair scientific ambition with disciplined validation, operational resilience, responsible AI governance, and explicit attention to equity.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. mRNA Cancer Vaccines & Therapeutics Market, by Indication
7.1. Introduction
7.2. Prostate Cancer
7.3. Pancreatic Cancer
7.4. Ovarian Cancer
7.5. Melanoma
7.6. Lung Cancer
7.7. Liver Cancer
7.8. Colorectal Cancer
7.9. Breast Cancer
8. mRNA Cancer Vaccines & Therapeutics Market, by Therapy Modality
8.1. Introduction
8.2. mRNA Encoded Therapeutic Proteins
8.3. mRNA Encoded Cell Therapies
8.4. Self Amplifying mRNA Therapeutics
8.5. Personalized Neoantigen Vaccines
8.6. Off The Shelf Tumor Associated Antigen Vaccines
9. mRNA Cancer Vaccines & Therapeutics Market, by Technology Platform
9.1. Introduction
9.2. Viral Vector Based Delivery
9.3. Polymer Nanoparticles
9.4. Lipid Polymer Hybrids
9.5. Lipid Nanoparticles
9.6. Exosome Based Delivery
9.7. Electroporation And Physical Delivery
10. mRNA Cancer Vaccines & Therapeutics Market, by Stage Of Development
10.1. Introduction
10.2. Preclinical
10.3. Discovery And Research
10.4. Commercial Approved
10.5. Clinical Phase III
10.6. Clinical Phase II
10.7. Clinical Phase I
11. mRNA Cancer Vaccines & Therapeutics Market, by End User
11.1. Introduction
11.2. Specialty Pharmacies
11.3. Outpatient Oncology Clinics
11.4. Hospitals And Oncology Centers
11.5. Home Healthcare Providers
11.6. Contract Research Organizations
11.7. Academic Medical Centers And Research Hospitals
12. mRNA Cancer Vaccines & Therapeutics Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. mRNA Cancer Vaccines & Therapeutics Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. mRNA Cancer Vaccines & Therapeutics Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Abogen Biosciences Co., Ltd.
16.2. Arcturus Therapeutics Holdings Inc.
16.3. Averna Therapeutics, Inc.
16.4. BioNTech SE
16.5. CanSino Biologics Inc.
16.6. Cartesian Therapeutics, Inc.
16.7. CureVac SE
16.8. eTheRNA Immunotherapies NV
16.9. Ethris GmbH
16.10. Genevant Sciences GmbH
16.11. GreenLight Biosciences, Inc.
16.12. Gritstone bio, Inc.
16.13. Immorna Co., Ltd.
16.14. Kernal Biologics, Inc.
16.15. Moderna, Inc.
16.16. NeoCura Bio-Medical Technology Co., Ltd.
16.17. Nutcracker Therapeutics, Inc.
16.18. Orbital Therapeutics, Inc.
16.19. PopVax Pvt Ltd
16.20. Providence Therapeutics Holdings Inc.
16.21. RNAimmune, Inc.
16.22. RVAC Medicines
16.23. SAB Biotherapeutics, Inc.
16.24. Stemirna Therapeutics Co., Ltd.
16.25. Strand Therapeutics, Inc.
16.26. Translate Bio, Inc.
16.27. TriLink BioTechnologies, LLC
16.28. VaxEquity Ltd
16.29. Versameb AG
16.30. WestGene Biopharma Co., Ltd.
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global mRNA Cancer Vaccines & Therapeutics Market, Years Considered for the Study
FIGURE 2. Global mRNA Cancer Vaccines & Therapeutics Market, Research Design
FIGURE 3. Global mRNA Cancer Vaccines & Therapeutics Market, Research Framework
FIGURE 4. Global mRNA Cancer Vaccines & Therapeutics Market, Data Triangulation
FIGURE 5. Global mRNA Cancer Vaccines & Therapeutics Market Size, 2017-2032 (USD Million)
FIGURE 6. Global mRNA Cancer Vaccines & Therapeutics Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 7. Global mRNA Cancer Vaccines & Therapeutics Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global mRNA Cancer Vaccines & Therapeutics Market Size, by Therapy Modality, 2025 vs 2032 (%)
FIGURE 9. Global mRNA Cancer Vaccines & Therapeutics Market Size, by Therapy Modality, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global mRNA Cancer Vaccines & Therapeutics Market Size, by Technology Platform, 2025 vs 2032 (%)
FIGURE 11. Global mRNA Cancer Vaccines & Therapeutics Market Size, by Technology Platform, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global mRNA Cancer Vaccines & Therapeutics Market Size, by Stage Of Development, 2025 vs 2032 (%)
FIGURE 13. Global mRNA Cancer Vaccines & Therapeutics Market Size, by Stage Of Development, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global mRNA Cancer Vaccines & Therapeutics Market Size, by End User, 2025 vs 2032 (%)
FIGURE 15. Global mRNA Cancer Vaccines & Therapeutics Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global mRNA Cancer Vaccines & Therapeutics Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global mRNA Cancer Vaccines & Therapeutics Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global mRNA Cancer Vaccines & Therapeutics Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global mRNA Cancer Vaccines & Therapeutics Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global mRNA Cancer Vaccines & Therapeutics Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global mRNA Cancer Vaccines & Therapeutics Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global mRNA Cancer Vaccines & Therapeutics Market Segmentation & Coverage
TABLE 2. Global mRNA Cancer Vaccines & Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 3. Global mRNA Cancer Vaccines & Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 4. Global Prostate Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Prostate Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Prostate Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Pancreatic Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Pancreatic Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Pancreatic Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Ovarian Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Ovarian Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Ovarian Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Melanoma Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Melanoma Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Melanoma Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Lung Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Lung Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Lung Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Liver Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Liver Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Liver Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Colorectal Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Colorectal Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Colorectal Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Breast Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Breast Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Breast Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global mRNA Cancer Vaccines & Therapeutics Market Size, by Therapy Modality, 2017-2032 (USD Million)
TABLE 29. Global mRNA Encoded Therapeutic Proteins Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global mRNA Encoded Therapeutic Proteins Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global mRNA Encoded Therapeutic Proteins Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global mRNA Encoded Cell Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 33. Global mRNA Encoded Cell Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 34. Global mRNA Encoded Cell Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 35. Global Self Amplifying mRNA Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Self Amplifying mRNA Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Self Amplifying mRNA Therapeutics Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global Personalized Neoantigen Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Personalized Neoantigen Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Personalized Neoantigen Vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Off The Shelf Tumor Associated Antigen Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Off The Shelf Tumor Associated Antigen Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Off The Shelf Tumor Associated Antigen Vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global mRNA Cancer Vaccines & Therapeutics Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 45. Global Viral Vector Based Delivery Market Size, by Region, 2017-2032 (USD Million)
TABLE 46. Global Viral Vector Based Delivery Market Size, by Group, 2017-2032 (USD Million)
TABLE 47. Global Viral Vector Based Delivery Market Size, by Country, 2017-2032 (USD Million)
TABLE 48. Global Polymer Nanoparticles Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Polymer Nanoparticles Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Polymer Nanoparticles Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Lipid Polymer Hybrids Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Lipid Polymer Hybrids Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Lipid Polymer Hybrids Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Lipid Nanoparticles Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global Lipid Nanoparticles Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global Lipid Nanoparticles Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global Exosome Based Delivery Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. Global Exosome Based Delivery Market Size, by Group, 2017-2032 (USD Million)
TABLE 59. Global Exosome Based Delivery Market Size, by Country, 2017-2032 (USD Million)
TABLE 60. Global Electroporation And Physical Delivery Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. Global Electroporation And Physical Delivery Market Size, by Group, 2017-2032 (USD Million)
TABLE 62. Global Electroporation And Physical Delivery Market Size, by Country, 2017-2032 (USD Million)
TABLE 63. Global mRNA Cancer Vaccines & Therapeutics Market Size, by Stage Of Development, 2017-2032 (USD Million)
TABLE 64. Global Preclinical Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Global Preclinical Market Size, by Group, 2017-2032 (USD Million)
TABLE 66. Global Preclinical Market Size, by Country, 2017-2032 (USD Million)
TABLE 67. Global Discovery And Research Market Size, by Region, 2017-2032 (USD Million)
TABLE 68. Global Discovery And Research Market Size, by Group, 2017-2032 (USD Million)
TABLE 69. Global Discovery And Research Market Size, by Country, 2017-2032 (USD Million)
TABLE 70. Global Commercial Approved Market Size, by Region, 2017-2032 (USD Million)
TABLE 71. Global Commercial Approved Market Size, by Group, 2017-2032 (USD Million)
TABLE 72. Global Commercial Approved Market Size, by Country, 2017-2032 (USD Million)
TABLE 73. Global Clinical Phase III Market Size, by Region, 2017-2032 (USD Million)
TABLE 74. Global Clinical Phase III Market Size, by Group, 2017-2032 (USD Million)
TABLE 75. Global Clinical Phase III Market Size, by Country, 2017-2032 (USD Million)
TABLE 76. Global Clinical Phase II Market Size, by Region, 2017-2032 (USD Million)
TABLE 77. Global Clinical Phase II Market Size, by Group, 2017-2032 (USD Million)
TABLE 78. Global Clinical Phase II Market Size, by Country, 2017-2032 (USD Million)
TABLE 79. Global Clinical Phase I Market Size, by Region, 2017-2032 (USD Million)
TABLE 80. Global Clinical Phase I Market Size, by Group, 2017-2032 (USD Million)
TABLE 81. Global Clinical Phase I Market Size, by Country, 2017-2032 (USD Million)
TABLE 82. Global mRNA Cancer Vaccines & Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 83. Global Specialty Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 84. Global Specialty Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 85. Global Specialty Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 86. Global Outpatient Oncology Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 87. Global Outpatient Oncology Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 88. Global Outpatient Oncology Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 89. Global Hospitals And Oncology Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 90. Global Hospitals And Oncology Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 91. Global Hospitals And Oncology Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 92. Global Home Healthcare Providers Market Size, by Region, 2017-2032 (USD Million)
TABLE 93. Global Home Healthcare Providers Market Size, by Group, 2017-2032 (USD Million)
TABLE 94. Global Home Healthcare Providers Market Size, by Country, 2017-2032 (USD Million)
TABLE 95. Global Contract Research Organizations Market Size, by Region, 2017-2032 (USD Million)
TABLE 96. Global Contract Research Organizations Market Size, by Group, 2017-2032 (USD Million)
TABLE 97. Global Contract Research Organizations Market Size, by Country, 2017-2032 (USD Million)
TABLE 98. Global Academic Medical Centers And Research Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 99. Global Academic Medical Centers And Research Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 100. Global Academic Medical Centers And Research Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 101. Global mRNA Cancer Vaccines & Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 102. Asia-Pacific mRNA Cancer Vaccines & Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 103. Asia-Pacific mRNA Cancer Vaccines & Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 104. Asia-Pacific mRNA Cancer Vaccines & Therapeutics Market Size, by Therapy Modality, 2017-2032 (USD Million)
TABLE 105. Asia-Pacific mRNA Cancer Vaccines & Therapeutics Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 106. Asia-Pacific mRNA Cancer Vaccines & Therapeutics Market Size, by Stage Of Development, 2017-2032 (USD Million)
TABLE 107. Asia-Pacific mRNA Cancer Vaccines & Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 108. North America mRNA Cancer Vaccines & Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 109. North America mRNA Cancer Vaccines & Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 110. North America mRNA Cancer Vaccines & Therapeutics Market Size, by Therapy Modality, 2017-2032 (USD Million)
TABLE 111. North America mRNA Cancer Vaccines & Therapeutics Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 112. North America mRNA Cancer Vaccines & Therapeutics Market Size, by Stage Of Development, 2017-2032 (USD Million)
TABLE 113. North America mRNA Cancer Vaccines & Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 114. Latin America mRNA Cancer Vaccines & Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 115. Latin America mRNA Cancer Vaccines & Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 116. Latin America mRNA Cancer Vaccines & Therapeutics Market Size, by Therapy Modality, 2017-2032 (USD Million)
TABLE 117. Latin America mRNA Cancer Vaccines & Therapeutics Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 118. Latin America mRNA Cancer Vaccines & Therapeutics Market Size, by Stage Of Development, 2017-2032 (USD Million)
TABLE 119. Latin America mRNA Cancer Vaccines & Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 120. Europe mRNA Cancer Vaccines & Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 121. Europe mRNA Cancer Vaccines & Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 122. Europe mRNA Cancer Vaccines & Therapeutics Market Size, by Therapy Modality, 2017-2032 (USD Million)
TABLE 123. Europe mRNA Cancer Vaccines & Therapeutics Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 124. Europe mRNA Cancer Vaccines & Therapeutics Market Size, by Stage Of Development, 2017-2032 (USD Million)
TABLE 125. Europe mRNA Cancer Vaccines & Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 126. Middle East mRNA Cancer Vaccines & Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 127. Middle East mRNA Cancer Vaccines & Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 128. Middle East mRNA Cancer Vaccines & Therapeutics Market Size, by Therapy Modality, 2017-2032 (USD Million)
TABLE 129. Middle East mRNA Cancer Vaccines & Therapeutics Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 130. Middle East mRNA Cancer Vaccines & Therapeutics Market Size, by Stage Of Development, 2017-2032 (USD Million)
TABLE 131. Middle East mRNA Cancer Vaccines & Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 132. Africa mRNA Cancer Vaccines & Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 133. Africa mRNA Cancer Vaccines & Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 134. Africa mRNA Cancer Vaccines & Therapeutics Market Size, by Therapy Modality, 2017-2032 (USD Million)
TABLE 135. Africa mRNA Cancer Vaccines & Therapeutics Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 136. Africa mRNA Cancer Vaccines & Therapeutics Market Size, by Stage Of Development, 2017-2032 (USD Million)
TABLE 137. Africa mRNA Cancer Vaccines & Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 138. Global mRNA Cancer Vaccines & Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 139. ASEAN mRNA Cancer Vaccines & Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 140. ASEAN mRNA Cancer Vaccines & Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 141. ASEAN mRNA Cancer Vaccines & Therapeutics Market Size, by Therapy Modality, 2017-2032 (USD Million)
TABLE 142. ASEAN mRNA Cancer Vaccines & Therapeutics Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 143. ASEAN mRNA Cancer Vaccines & Therapeutics Market Size, by Stage Of Development, 2017-2032 (USD Million)
TABLE 144. ASEAN mRNA Cancer Vaccines & Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 145. GCC mRNA Cancer Vaccines & Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 146. GCC mRNA Cancer Vaccines & Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 147. GCC mRNA Cancer Vaccines & Therapeutics Market Size, by Therapy Modality, 2017-2032 (USD Million)
TABLE 148. GCC mRNA Cancer Vaccines & Therapeutics Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 149. GCC mRNA Cancer Vaccines & Therapeutics Market Size, by Stage Of Development, 2017-2032 (USD Million)
TABLE 150. GCC mRNA Cancer Vaccines & Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 151. European Union mRNA Cancer Vaccines & Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 152. European Union mRNA Cancer Vaccines & Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 153. European Union mRNA Cancer Vaccines & Therapeutics Market Size, by Therapy Modality, 2017-2032 (USD Million)
TABLE 154. European Union mRNA Cancer Vaccines & Therapeutics Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 155. European Union mRNA Cancer Vaccines & Therapeutics Market Size, by Stage Of Development, 2017-2032 (USD Million)
TABLE 156. European Union mRNA Cancer Vaccines & Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 157. BRICS mRNA Cancer Vaccines & Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 158. BRICS mRNA Cancer Vaccines & Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 159. BRICS mRNA Cancer Vaccines & Therapeutics Market Size, by Therapy Modality, 2017-2032 (USD Million)
TABLE 160. BRICS mRNA Cancer Vaccines & Therapeutics Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 161. BRICS mRNA Cancer Vaccines & Therapeutics Market Size, by Stage Of Development, 2017-2032 (USD Million)
TABLE 162. BRICS mRNA Cancer Vaccines & Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 163. G7 mRNA Cancer Vaccines & Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 164. G7 mRNA Cancer Vaccines & Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 165. G7 mRNA Cancer Vaccines & Therapeutics Market Size, by Therapy Modality, 2017-2032 (USD Million)
TABLE 166. G7 mRNA Cancer Vaccines & Therapeutics Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 167. G7 mRNA Cancer Vaccines & Therapeutics Market Size, by Stage Of Development, 2017-2032 (USD Million)
TABLE 168. G7 mRNA Cancer Vaccines & Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 169. NATO mRNA Cancer Vaccines & Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 170. NATO mRNA Cancer Vaccines & Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 171. NATO mRNA Cancer Vaccines & Therapeutics Market Size, by Therapy Modality, 2017-2032 (USD Million)
TABLE 172. NATO mRNA Cancer Vaccines & Therapeutics Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 173. NATO mRNA Cancer Vaccines & Therapeutics Market Size, by Stage Of Development, 2017-2032 (USD Million)
TABLE 174. NATO mRNA Cancer Vaccines & Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 175. Global mRNA Cancer Vaccines & Therapeutics Market Size, by Country, 2017-2032 (USD Million)
TABLE 176. United States mRNA Cancer Vaccines & Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 177. United States mRNA Cancer Vaccines & Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 178. United States mRNA Cancer Vaccines & Therapeutics Market Size, by Therapy Modality, 2017-2032 (USD Million)
TABLE 179. United States mRNA Cancer Vaccines & Therapeutics Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 180. United States mRNA Cancer Vaccines & Therapeutics Market Size, by Stage Of Development, 2017-2032 (USD Million)
TABLE 181. United States mRNA Cancer Vaccines & Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 182. Canada mRNA Cancer Vaccines & Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 183. Canada mRNA Cancer Vaccines & Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 184. Canada mRNA Cancer Vaccines & Therapeutics Market Size, by Therapy Modality, 2017-2032 (USD Million)
TABLE 185. Canada mRNA Cancer Vaccines & Therapeutics Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 186. Canada mRNA Cancer Vaccines & Therapeutics Market Size, by Stage Of Development, 2017-2032 (USD Million)
TABLE 187. Canada mRNA Cancer Vaccines & Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 188. Mexico mRNA Cancer Vaccines & Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 189. Mexico mRNA Cancer Vaccines & Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 190. Mexico mRNA Cancer Vaccines & Therapeutics Market Size, by Therapy Modality, 2017-2032 (USD Million)
TABLE 191. Mexico mRNA Cancer Vaccines & Therapeutics Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 192. Mexico mRNA Cancer Vaccines & Therapeutics Market Size, by Stage Of Development, 2017-2032 (USD Million)
TABLE 193. Mexico mRNA Cancer Vaccines & Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 194. Brazil mRNA Cancer Vaccines & Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 195. Brazil mRNA Cancer Vaccines & Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 196. Brazil mRNA Cancer Vaccines & Therapeutics Market Size, by Therapy Modality, 2017-2032 (USD Million)
TABLE 197. Brazil mRNA Cancer Vaccines & Therapeutics Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 198. Brazil mRNA Cancer Vaccines & Therapeutics Market Size, by Stage Of Development, 2017-2032 (USD Million)
TABLE 199. Brazil mRNA Cancer Vaccines & Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 200. United Kingdom mRNA Cancer Vaccines & Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 201. United Kingdom mRNA Cancer Vaccines & Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 202. United Kingdom mRNA Cancer Vaccines & Therapeutics Market Size, by Therapy Modality, 2017-2032 (USD Million)
TABLE 203. United Kingdom mRNA Cancer Vaccines & Therapeutics Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 204. United Kingdom mRNA Cancer Vaccines & Therapeutics Market Size, by Stage Of Development, 2017-2032 (USD Million)
TABLE 205. United Kingdom mRNA Cancer Vaccines & Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 206. Germany mRNA Cancer Vaccines & Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 207. Germany mRNA Cancer Vaccines & Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 208. Germany mRNA Cancer Vaccines & Therapeutics Market Size, by Therapy Modality, 2017-2032 (USD Million)
TABLE 209. Germany mRNA Cancer Vaccines & Therapeutics Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 210. Germany mRNA Cancer Vaccines & Therapeutics Market Size, by Stage Of Development, 2017-2032 (USD Million)
TABLE 211. Germany mRNA Cancer Vaccines & Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 212. France mRNA Cancer Vaccines & Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 213. France mRNA Cancer Vaccines & Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 214. France mRNA Cancer Vaccines & Therapeutics Market Size, by Therapy Modality, 2017-2032 (USD Million)
TABLE 215. France mRNA Cancer Vaccines & Therapeutics Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 216. France mRNA Cancer Vaccines & Therapeutics Market Size, by Stage Of Development, 2017-2032 (USD Million)
TABLE 217. France mRNA Cancer Vaccines & Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 218. Russia mRNA Cancer Vaccines & Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 219. Russia mRNA Cancer Vaccines & Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 220. Russia mRNA Cancer Vaccines & Therapeutics Market Size, by Therapy Modality, 2017-2032 (USD Million)
TABLE 221. Russia mRNA Cancer Vaccines & Therapeutics Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 222. Russia mRNA Cancer Vaccines & Therapeutics Market Size, by Stage Of Development, 2017-2032 (USD Million)
TABLE 223. Russia mRNA Cancer Vaccines & Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 224. Italy mRNA Cancer Vaccines & Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 225. Italy mRNA Cancer Vaccines & Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 226. Italy mRNA Cancer Vaccines & Therapeutics Market Size, by Therapy Modality, 2017-2032 (USD Million)
TABLE 227. Italy mRNA Cancer Vaccines & Therapeutics Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 228. Italy mRNA Cancer Vaccines & Therapeutics Market Size, by Stage Of Development, 2017-2032 (USD Million)
TABLE 229. Italy mRNA Cancer Vaccines & Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 230. Spain mRNA Cancer Vaccines & Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 231. Spain mRNA Cancer Vaccines & Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 232. Spain mRNA Cancer Vaccines & Therapeutics Market Size, by Therapy Modality, 2017-2032 (USD Million)
TABLE 233. Spain mRNA Cancer Vaccines & Therapeutics Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 234. Spain mRNA Cancer Vaccines & Therapeutics Market Size, by Stage Of Development, 2017-2032 (USD Million)
TABLE 235. Spain mRNA Cancer Vaccines & Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 236. China mRNA Cancer Vaccines & Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 237. China mRNA Cancer Vaccines & Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 238. China mRNA Cancer Vaccines & Therapeutics Market Size, by Therapy Modality, 2017-2032 (USD Million)
TABLE 239. China mRNA Cancer Vaccines & Therapeutics Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 240. China mRNA Cancer Vaccines & Therapeutics Market Size, by Stage Of Development, 2017-2032 (USD Million)
TABLE 241. China mRNA Cancer Vaccines & Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 242. India mRNA Cancer Vaccines & Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 243. India mRNA Cancer Vaccines & Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 244. India mRNA Cancer Vaccines & Therapeutics Market Size, by Therapy Modality, 2017-2032 (USD Million)
TABLE 245. India mRNA Cancer Vaccines & Therapeutics Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 246. India mRNA Cancer Vaccines & Therapeutics Market Size, by Stage Of Development, 2017-2032 (USD Million)
TABLE 247. India mRNA Cancer Vaccines & Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 248. Japan mRNA Cancer Vaccines & Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 249. Japan mRNA Cancer Vaccines & Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 250. Japan mRNA Cancer Vaccines & Therapeutics Market Size, by Therapy Modality, 2017-2032 (USD Million)
TABLE 251. Japan mRNA Cancer Vaccines & Therapeutics Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 252. Japan mRNA Cancer Vaccines & Therapeutics Market Size, by Stage Of Development, 2017-2032 (USD Million)
TABLE 253. Japan mRNA Cancer Vaccines & Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 254. Australia mRNA Cancer Vaccines & Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 255. Australia mRNA Cancer Vaccines & Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 256. Australia mRNA Cancer Vaccines & Therapeutics Market Size, by Therapy Modality, 2017-2032 (USD Million)
TABLE 257. Australia mRNA Cancer Vaccines & Therapeutics Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 258. Australia mRNA Cancer Vaccines & Therapeutics Market Size, by Stage Of Development, 2017-2032 (USD Million)
TABLE 259. Australia mRNA Cancer Vaccines & Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 260. South Korea mRNA Cancer Vaccines & Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 261. South Korea mRNA Cancer Vaccines & Therapeutics Market Size, by Indication, 2017-2032 (USD Million)
TABLE 262. South Korea mRNA Cancer Vaccines & Therapeutics Market Size, by Therapy Modality, 2017-2032 (USD Million)
TABLE 263. South Korea mRNA Cancer Vaccines & Therapeutics Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 264. South Korea mRNA Cancer Vaccines & Therapeutics Market Size, by Stage Of Development, 2017-2032 (USD Million)
TABLE 265. South Korea mRNA Cancer Vaccines & Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 266. Global mRNA Cancer Vaccines & Therapeutics Market Share, by Key Player, 2025
TABLE 267. Global mRNA Cancer Vaccines & Therapeutics Market, Key Experts

Companies Mentioned

  • Abogen Biosciences Co., Ltd.
  • Arcturus Therapeutics Holdings Inc.
  • Averna Therapeutics, Inc.
  • BioNTech SE
  • CanSino Biologics Inc.
  • Cartesian Therapeutics, Inc.
  • CureVac SE
  • eTheRNA Immunotherapies NV
  • Ethris GmbH
  • Genevant Sciences GmbH
  • GreenLight Biosciences, Inc.
  • Gritstone bio, Inc.
  • Immorna Co., Ltd.
  • Kernal Biologics, Inc.
  • Moderna, Inc.
  • NeoCura Bio-Medical Technology Co., Ltd.
  • Nutcracker Therapeutics, Inc.
  • Orbital Therapeutics, Inc.
  • PopVax Pvt Ltd
  • Providence Therapeutics Holdings Inc.
  • RNAimmune, Inc.
  • RVAC Medicines
  • SAB Biotherapeutics, Inc.
  • Stemirna Therapeutics Co., Ltd.
  • Strand Therapeutics, Inc.
  • Translate Bio, Inc.
  • TriLink BioTechnologies, LLC
  • VaxEquity Ltd
  • Versameb AG
  • WestGene Biopharma Co., Ltd.

Related Topics

Related Reports

mRNA Cancer Vaccine Market Report 2026-2036 - Product Image

mRNA Cancer Vaccine Market Report 2026-2036

  • Report
  • 289 Pages
  • Global
From
mRNA Cancer Vaccines Clinical Trials, Market Trends By Indication, Development Priority Status & Market Opportunity Insight 2025 - Product Image

mRNA Cancer Vaccines Clinical Trials, Market Trends By Indication, Development Priority Status & Market Opportunity Insight 2025

  • Drug Pipelines
  • 150 Pages
  • Global
From
Global mRNA Cancer Vaccines Market Opportunity, Therapeutic Development Proprietary Technologies & Clinical Trials Insight 2026 - Product Image

Global mRNA Cancer Vaccines Market Opportunity, Therapeutic Development Proprietary Technologies & Clinical Trials Insight 2026

  • Report
  • 190 Pages
  • Global
From
MRNA Cancer Vaccine and Therapeutic Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

MRNA Cancer Vaccine and Therapeutic Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 181 Pages
  • Global
From
mRNA Vaccines Market by Target Indication (RSV Infection, Metastatic / R / R Head and Neck Cancer, Influenza, Norovirus Acute Gastroenteritis, and Mononucleosis) and Geographical Regions (North America, Europe, and Asia-Pacific) - Trends and Forecast Till 2035 - Product Image

mRNA Vaccines Market by Target Indication (RSV Infection, Metastatic / R / R Head and Neck Cancer, Influenza, Norovirus Acute Gastroenteritis, and Mononucleosis) and Geographical Regions (North America, Europe, and Asia-Pacific) - Trends and Forecast Till 2035

  • Report
  • 269 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.